A leader in the development and application of information technology to prevent and treat disease.

Transcription

1 A leader in the development and application of information technology to prevent and treat disease.

2 About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today we are leaders in the development and application of information technology to prevent and treat disease. Over the last 10 years, we have designed, built, and verified technology-driven products that are changing the way diseases are analyzed, understood, and treated. The decoding of the first human genome in 2000 ushered in a new era for medicine. Known as precision medicine, it sets out to find the best possible treatment for each patient based upon his or her individual genetic uniqueness. Today, every patient can benefit from the scientific and technological innovations in the field of human genome analysis. The challenge in delivering precision medicine is mapping the molecular and clinical information of a patient against all the relevant medical knowledge in a way that yields a timely and practical personalized application. To do so requires a new type of information technology. Molecular Health is at the forefront of this paradigm shift. Merging information technology with science and clinical applications, we create groundbreaking products that help to radically improve the prevention and treatment of diseases like cancer.

3 Nucleus Genes and proteins Indications and disease classification Drug-drug interactions Biomarkers Publications Clinical trials Signal transduction pathways Drugs The biomedical knowledge database Nucleus contains the knowledge of over 22 million publications, over 90,000 clinical trials, over 5,000 biomarkers for drug efficacy and safety, over 23,000 drug drug interactions, over 36,000 drugs, and 600 cancer indications. Our expert team is continuously working to expand the knowledge database, staying on top of current, breakthrough scientific findings and advanced computational methods for clinical interpretation. One of the most comprehensive biomedical knowledge databases in the world. Regularly fed with the latest information that clinicians and researchers need in order to interpret complex molecular patient information, such as cancer genomes. Aggregates and harmonizes the often disparate and constantly growing volume of clinical and molecular information. It is a unique, reliable and precise reference system for biomedical information.

4 Building the big data universe We work with a large and constantly growing number of external reference databases from all over the world, across all medical disciplines. In order to extract relevant information and reformat it for loading into Nucleus, we have developed a suite of ETL (extract, transform, and load) processes. Our knowledge mining technology captures valuable biomedical data from within text and other unstructured formats. This provides immediate access to new data that has not yet been entered into any database or guideline. Our scientific domain experts constantly review the process of producing, analyzing, and detailing new data. We have developed the Molecular Health Curation application to facilitate this process. In order to move beyond simply collecting information, we built a platform infrastructure allowing us to discover new knowledge in unstructured data, to refine it, and to produce new, quality-assured, and value-added precision medicine databases. For example, we use the information in Nucleus to produce novel, high-quality reference databases, such as the Molecular Health Drug database and the Molecular Health Biomarker database. Biomarkers are essential for the precise molecular characterization of diseases, inherited disease risk analysis, drug toxicity risk analysis, and treatment efficacy. The Molecular Health Biomarker database within Nucleus is a first-in-class, proprietary biomarker database that holds data for thousands of biomarkers, including the underlying evidence for each of them. The Molecular Health Drug database stores information about the molecular mechanism of drug action, drug drug interactions, drug targets, detailed drug development status, and metabolizing enzymes.

5 Analytical Software Components Our analytical software components match molecular and clinical patient data with the knowledge in Nucleus to provide evidence-driven reports that enable optimized decision making. InsightMAP InsightMAP is a flexible custom solution built on our Nucleus core technology in conjunction with clinical and genomic patient data. With InsightMAP it is possible to formulate and resolve complex research questions relating to genome analysis of large patient cohorts. For example, it helps pharmaceutical firms optimize their drug development and diagnostics development processes. InsightMAP comprises professional research services and custom solutions for patient cohort stratification to be used for clinical trial design; drug mechanisms of action, resistance, and toxicity research; and outcome analytics for the pharmaceutical industry and other research customers, for example, large clinical centers. Helps open new therapeutic areas for existing drugs and targeted clinical trials Utilizes the growing knowledge about disese classifiers to increase drug responder rate Retrospective analysis of IP-protected data about drug/diagnostics development Reduces risk of drug failure in clinical trials Speeds up drug and companion diagnostics development Helps prioritize discovery projects Helps identify future therapeutic targets By utilizing the knowledge stored in Nucleus in combination with our analytical software components, our scientists identified a novel receptor EPH-B4, for Erythropoietin (EPO).

6 TreatmentMAP TreatmentMAP is a globally unique bioinformatics solution for the automated analysis of next-generation sequencing (NGS) data from cancer patients, providing clinical treatment decision support. With TreatmentMAP, thousands of data points in complex clinical and molecular data sets can be automatically analyzed against current biomedical knowledge that is required for clinical and translational application. The treatment decision support system helps physicians optimize cancer treatment plans by identifying options that best match the molecular profile of their patients. In addition to an end-to-end clinical service, Molecular Health offers TreatmentMAP as a stand-alone hosted software solution, which enables medical service providers to standardize, automate, and ensure quality control of clinical interpretation of genome data. Comprehensive profiling of tumor and control genomes Efficacy and safety biomarker detection and treatment prioritization Candidate biomarker identification and biomarker inference Mapping of complex genomic profiles to biomedical reference information Analysis of network effects of genetic variants based on cell signaling pathways Interpretation and prioritization of genetic variants of unknown biological and clinical relevance Automated quality monitoring of genome analysis and workflow Treatment de-risking based on drug mechanisms and metabolism SafetyMAP SafetyMAP is a content and analytics solution that can be used with or without molecular patient data for individual drug de-risking and drug safety analysis. It can be used by researchers, pharmaceutical companies, regulatory authorities, and health insurers. Exploration and prediction of potentially causative molecular mechanisms Analysis of adverse event data for drugs, drug classes, targets, or pathways Comparative effectiveness and comparative safety analyses Safety signal detection and analysis Definition and analysis of virtual patient cohorts Molecular analysis of individual patients Can be extended to include results from clinical trial and adverse drug event management programs

7 Our unique technology advantage: The comprehensive knowledge platform for Precision Medicine From end-to-end clinical service to technology platform sales, we cover the entire spectrum of healthcare industry needs. Advanced information technology and databases Text-data-mining, data curation, chemoinformatics, bioinformatics, data analytics, disease models, outcomes database, evidence-based clinical interpretation. In-depth clinical interpretation capability We offer technology that enables integrated analysis of tumor, germline and pharmacological data. NGS panel: comprehensive and clinically actionable Computationally designed for cancer genome analysis over 3 million publications screened, over 600 actionable genes, over 160 predictive biomarkers, and over 320 cancer drug targets. Relevant treatment decision report Designed by oncologists and pathologists. Addresses key pain-points of the healthcare industry: Summary of the potential therapy options based on biomarkers identified in the patient s genetic profile Direct access to supporting evidence, including drug profiles and up-to-date knowledge on genetic variants Safety analysis to identify biomarkers in the patient s genetic profile that have been reported to predict either lack of response to treatment or safety issues Information about ongoing clinical trials for the identified therapy options Evidence-driven treatment options and safety concerns Detailed clinical evidence summarizes published patient outcomes. Molecular Health GmbH is audited and certified as per DIN EN ISO Molecular Health Inc. NGS Sequencing Laboratory in the US is CAP accredited Molecular Health Inc. NGS Sequencing Laboratory in the US is CLIA certified

8 Heidelberg, Germany Greater Houston, Texas Cambridge, Massachusetts T T T E germany@molecularhealth.com E us@molecularhealth.com E us@molecularhealth.com Molecular Health GmbH Kurfuersten-Anlage Heidelberg Germany US Support Center US Corporate Office CLIA/CAP Laboratory 245 First Street Riverview II, 18th Floor 2700 Technology Forest Cambridge, MA The Woodlands, TX USA USA Copyright 2015, Molecular Health GmbH. All rights reserved. CO-GA-BR0415-BA